Research and analysis

ACRE advice: application for a vaccine trial of genetically modified Respiratory Syncytial Virus (24/R56/01)

ACRE’s advice on an application from Sanofi Pasteur Inc. to carry out a vaccine trial using genetically modified Respiratory Syncytial Virus.

• From: Advisory Committee on Releases to the Environment
• Published: 10 May 2024

Documents

ACRE advice: application for a vaccine trial of genetically modified Respiratory Syncytial Virus (24/R56/01)

PDF, 209 KB, 5 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

These documents are the advice of the Advisory Committee on Releases to the Environment (ACRE) to government on an application from Sanofi Pasteur, Inc. to carry out a vaccine trial of genetically modified Respiratory Syncytial Virus.

The committee advised that the risks to human health and the environment from this trial are extremely low.

Published 10 May 2024